Revenue Cycle Management: $7Bn R1 RCM deal shines light on revenue cycle market
Lloyd Price
Partner at Nelson Advisors > Healthcare Technology Mergers & Acquisitions, Growth & Strategy. Non Executive Director > Digital Health Portfolio. Founder of Zesty > acquired by Induction Healthcare Group PLC (FTSE:INHC)
Nelson Advisors Partner and HealthTech M&A Advisor Lloyd Price sharing his thoughts on the Revenue Cycle Management (RCM) market and USD $7Bn bid for R1 RCM with the team at MergerMarket
Revenue cycle management (RCM) has become one of the brightest stars in the healthcare technology firmament after the USD $7Bn bid for R1 RCM [NASDAQ:RCM] from private-equity groups TowerBrook Capital Partners and Clayton, Dubilier & Rice on 1st August.
The attraction is simple: Financial sponsors and strategics continue to see blue sky for growth both organically and through acquisition in a highly fragmented market that quite literally pays the bills in healthcare.
RCM software helps hospitals, doctors and other healthcare groups bill for services and collect payments.
“It’s clearly at the top of the pyramid” for healthcare information technology (HCIT) players, says Mark Cherney, managing director of The Cherney Group, an advisory to private equity and family offices in the healthcare services area. “It can make the difference between profitability and not.”
“Improving collections and preventing denials improves cash flow and the bottom line for healthcare providers, especially in a time of razor-thin margins and increasingly complex and onerous coding and reimbursement rules and regulations,” adds Michael Siano, managing director and HCIT lead at Lincoln International.
Private equity play
One major tailwind that provides RCM companies with a large and growing addressable market is the aging of the American population, adds Siano. More than 46 million adults aged 65 and older live in the US, a number that is expected to almost double by 2050, according to some industry estimates.
Private equity likes RCM players primarily because they have long-term contracts with healthcare providers that offer strong and predictable revenue streams, according to Lloyd Price, a partner at Nelson Advisors specializing in healthcare. They are also scalable and have the potential for operational improvement. And because healthcare providers only need one RCM system, the relationship tends to be sticky, he adds.
Other deals are likely to follow suit, predicts Price.
Cherney says he consults with 40-50 financial sponsors on a regular basis, and “they’re all looking, they’re all interested” in R1 RCM or a peer of appropriate size and expertise in the billing and collections business primarily.
Technology-driven RCM companies can command multiples of 20x EBITDA or more, say dealmakers. In April, Model N agreed to a USD 1.28 Bn buyout by Vista Equity Partners for USD 1.28 Bn, roughly a 25x multiple of EBITDA, according to one HCIT banker.
More services-driven RCM players see lower multiples in the mid-to-high teens, say dealmakers. RevSpring, a healthcare IT company, sold in March to a group led by Frazier Healthcare Partners for USD $1.3Bn, or roughly 13x EBITDA, this news service reported.
The RCM landscape
Some RCM groups are focused on one specialty such as ambulatory surgery centers, others are multi-specialty. Yet others offer RCM packaged with other software, such as electronic medical records, practice management or patient engagement tools. All are seen as attractive potential targets.
Only a handful of large players with more than USD 100m in EBITDA exist, according to Siano. Besides R1 RCM, other large players include Ensemble Health Partners (backed by Berkshire Partners and Warburg Pincus) and Carlyle-backed CorroHealth.
Few mid-market players with around USD 30m to USD 100m in EBITDA exist too. They include ChrysCapital-backed GeBBS Healthcare Solutions. Most players have less than USD 30m in EBITDA, says Siano.
Active pipeline
The most active private-equity buyers in the RCM space include Vista, KKR, Silver Lake and Carlyle Group, says Price. All have a history of investing in HCIT generally and any could make a rival bid for R1 RCM, says Price. One impediment: Towerbrook already owns a 36% stake.
In any case, the deals for R1 RCM, RevSpring and Model N should push other strong assets to market.
Recommended by LinkedIn
Mergermarket
Mergermarket blends market-leading human insights, advanced machine learning and 30+ years of Dealogic data to deliver the earliest possible signals of potential M&A opportunities, deals, threats and challenges.
Mergermarket is a service of ION Analytics.
Together we are transforming global capital markets with predictive analytics powered by human insights and machine learning. The ION Analytics platform brings together 6 unique, powerful services that span global markets making ION Analytics the only choice for capital markets professionals.
ION Analytics
ION Analytics fuses human insight and cutting-edge machine intelligence to ensure that the intricacies of global capital markets are not merely understood but anticipated.
We are not just part of this evolution; we are pioneering it. By merging human acumen with the expansive capabilities of AI we are continually transforming the landscape of capital allocation and formation for the better. Our services aren’t just intelligent, they’re intuitively adaptive. At ION Analytics, we’ve gone beyond providing mere precision.
Our solutions are predictive, accurate, and hyper-personalised, tailored to the multi-dimensional needs of our diverse clientele. The world’s leading capital market brands are at the heart of the thriving ION Analytics community. We are all evolving together – and you can too.
For us, it’s ultimately about one thing: your continuous success in the vital, ever-changing, always moving world of capital markets.
___________________________________________________________________________
Nelson Advisors work with Founders, Owners and Investors to assess whether they should 'Build, Buy, Partner or Sell' in order to maximise shareholder value.
> HealthTech M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk
> HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb
> HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk
> Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital/
#HealthTech #DigitalHealth #HealthIT #NelsonAdvisors #Mergers #Acquisitions #Growth #Strategy